HomeNewsScreenerMapsGroupsPortfolioInsiderFuturesForexCryptoCalendarPricing
Theme 		Help

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

Open in Screener

MBIO

Mustang Bio Inc

Last Close
Dec 30  •  04:00PM ET
0.9500
Dollar change
-0.0120
Percentage change
-1.25 %
Healthcare • Biotechnology • USA • NASD
Peers: CRSP FATE BLUE NTLA IOVA EDIT CLLS SGMO PGEN ADAP
 | Held by: VXF
Index- P/E- EPS (ttm)-1.27 Insider Own15.18% Shs Outstand6.45M Perf Week-14.41%
Market Cap6.93M Forward P/E- EPS next Y- Insider Trans-0.00% Shs Float6.19M Perf Month-32.62%
Enterprise Value-12.05M PEG- EPS next Q- Inst Own3.86% Short Float0.95% Perf Quarter-37.50%
Income-2.33M P/S- EPS this Y- Inst Trans-3.24% Short Ratio0.56 Perf Half Y-53.66%
Sales0.00M P/B0.71 EPS next Y- ROA-17.59% Short Interest0.06M Perf YTD-89.27%
Book/sh1.34 P/C0.37 EPS next 5Y- ROE-418.83% 52W High21.95 -95.67% Perf Year-89.20%
Cash/sh2.60 P/FCF- EPS past 3/5Y64.27% 51.52% ROIC-23.90% 52W Low0.89 6.43% Perf 3Y-99.66%
Dividend Est.- EV/EBITDA- Sales past 3/5Y- - Gross Margin- Volatility5.80% 6.78% Perf 5Y-99.96%
Dividend TTM- EV/Sales- EPS Y/Y TTM98.58% Oper. Margin- ATR (14)0.08 Perf 10Y-
Dividend Ex-Date- Quick Ratio2.05 Sales Y/Y TTM- Profit Margin- RSI (14)31.23 Recom1.00
Dividend Gr. 3/5Y- - Current Ratio2.05 EPS Q/Q96.08% SMA20-16.36% Beta2.09 Target Price500.00
Payout- Debt/Eq0.00 Sales Q/Q- SMA50-23.95% Rel Volume0.96 Prev Close0.96
Employees6 LT Debt/Eq0.00 Earnings- SMA200-33.94% Avg Volume104.54K Price0.95
IPOAug 22, 2017 Option/ShortNo / Yes EPS/Sales Surpr.-150.00% - Trades Volume101,639 Change-1.25%
Date Action Analyst Rating Change Price Target Change
May-18-21Initiated BTIG Research Buy $11
Oct-02-20Initiated B. Riley FBR Buy $9
Nov-20-19Initiated Cantor Fitzgerald Overweight $7
Aug-13-19Initiated H.C. Wainwright Buy $7
Jun-21-19Initiated Cantor Fitzgerald Overweight $7
Dec-21-17Initiated Oppenheimer Outperform $18
Jul-08-25 10:38AM
MBIO Soars on Orphan Drug Nod for Investigational Brain Cancer Therapy
(Zacks) -20.36%
Jul-07-25 08:30AM
Mustang Bio Granted Orphan Drug Designation by U.S. FDA for MB-101 (IL13Ra2-targeted CAR T-cells) to Treat Astrocytomas and Glioblastoma
(GlobeNewswire) +180.67%
Mar-05-25 04:15PM
Mustang Bio Regains Compliance with Nasdaq Capital Market Requirement
(GlobeNewswire) +5.56% -9.36%
Feb-27-25 04:05PM
Mustang Bio Announces Sale of Fixed Assets and Exit of Facility
(GlobeNewswire) -27.01%
Feb-11-25 04:10PM
Mustang Bio Regains Compliance with Nasdaq Minimum Bid Price Requirement
(GlobeNewswire)
08:00AM Loading…
Feb-10-25 08:00AM
Mustang Bio Announces Closing of $8 Million Public Offering
(GlobeNewswire) +5.40%
Feb-06-25 07:00AM
Mustang Bio Announces Pricing of $8 Million Public Offering
(GlobeNewswire)
Jan-14-25 08:00AM
Mustang Bio Announces Reverse Stock Split
(GlobeNewswire) -35.77%
Nov-12-24 08:30AM
Mustang Bio Receives Positive Listing Determination from Nasdaq
(GlobeNewswire)
Nov-08-24 06:36AM
Mustang Bios MB-108 receives FDA orphan drug status for glioma treatment
(Pharmaceutical Technology)
Nov-07-24 08:30AM
Mustang Bio Granted Orphan Drug Designation by U.S. FDA for MB-108 (HSV-1 oncolytic virus) to Treat Malignant Glioma
(GlobeNewswire)
Oct-26-24 05:20PM
Mustang Bio Secures $4M through Strategic Warrant Agreement
(TipRanks)
Oct-24-24 02:10PM
Mustang Bio Announces Exercise of Warrants for $4 Million Gross Proceeds
(GlobeNewswire)
Jun-28-24 08:00AM
Diamond Equity Research Releases Update Note on Enveric Biosciences Inc. (NASDAQ: ENVB)
(GlobeNewswire)
Jun-21-24 04:01PM
Mustang Bio Announces Closing of $2.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
(GlobeNewswire)
05:26PM Loading…
Jun-20-24 05:26PM
Biotech Advances Propel Oncology Market to $564.5B Amid Youth Cancer Spike
(PR Newswire) -34.07%
08:00AM
Mustang Bio Announces $2.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
(GlobeNewswire)
07:28AM
Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
(InvestorPlace)
Jun-18-24 10:22AM
Mustang (MBIO) Soars 477% on Data From Rare Blood Cancer Study
(Zacks) +13.35%
07:37AM
Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
(InvestorPlace)
07:30AM
Citi raises its S&P 500 target, Boeing CEO testifies: Yahoo Finance
(Yahoo Finance Video)
Jun-17-24 01:28PM
ACHR Stock Alert: Archer Aviation Strikes New Deal With Signature Aviation
(InvestorPlace) +476.92%
01:03PM
AAN Stock Alert: The Aaron's Company Pops 33% on Take-Private Deal
(InvestorPlace)
12:07PM
Why Is Mustang Bio (MBIO) Stock Up 347% Today?
(InvestorPlace)
08:30AM
Mustang Bio Announces Favorable Efficacy and Safety Data from Complete Waldenstrom Macroglobulinemia Cohort of Phase 1/2 Clinical Trial of MB-106, CD20-Targeted Autologous CAR-T Therapy
(GlobeNewswire)
May-22-24 08:04AM
Why Is Mustang Bio (MBIO) Stock Up 58% Today?
(InvestorPlace) -22.58%
07:23AM
Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
(InvestorPlace)
May-16-24 10:53AM
MBIO Stock Earnings: Mustang Bio Beats EPS for Q1 2024
(InvestorPlace) +8.54%
May-02-24 04:01PM
Mustang Bio Announces Closing of $4 Million Public Offering
(GlobeNewswire) +12.65% +8.46%
Apr-30-24 06:03AM
Mustang Bio Prices Public Offering of 16.9 Million Shares, Accompanying Warrants
(MT Newswires)
08:00PM Loading…
Apr-29-24 08:00PM
Mustang Bio Announces Pricing of $4 Million Public Offering
(GlobeNewswire) -25.02%
Mar-28-24 04:05PM
Fortress Biotech Reports 2023 Financial Results and Recent Corporate Highlights
(GlobeNewswire) +10.64%
09:00AM
Mustang Bio Announces Vision for CAR T-Cell Therapy Platform Expansion into Autoimmune Diseases
(GlobeNewswire)
Mar-11-24 04:05PM
Mustang Bio Reports Full-Year 2023 Financial Results and Recent Corporate Highlights
(GlobeNewswire) -7.20% -8.62%
Mar-07-24 07:30AM
Mustang Bio Announces Publication in Nature Medicine of Data from Phase 1 Trial Evaluating MB-101 IL13R 2-targeted CAR T-Cells in High-Grade Glioma
(GlobeNewswire) +5.30%
Jan-11-24 08:30AM
Mustang Bio to Participate in the B. Riley Securities 4th Annual Oncology Conference
(GlobeNewswire)
Dec-11-23 08:30AM
Mustang Bio Presents Updated Phase 1/2 Multicenter Clinical Data for MB-106 at the 2023 American Society of Hematology (ASH) Annual Meeting
(GlobeNewswire) -7.14%
Nov-14-23 04:05PM
Mustang Bio Reports Third Quarter 2023 Financial Results and Recent Corporate Highlights
(GlobeNewswire)
Nov-02-23 09:28AM
Mustang Bio Announces MB-106 CD20-Targeted CAR-T Data Selected for Presentation at 65th American Society of Hematology (ASH) Annual Meeting
(GlobeNewswire)
Oct-30-23 02:15PM
Mustang Bio Announces Closing of $4.4 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
(GlobeNewswire)
Oct-26-23 12:30PM
Mustang Bio Announces $4.4 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
(GlobeNewswire) -10.19%
09:00AM
Mustang Bio Announces FDA Acceptance of IND Application for MB-109, a Novel Combination of MB-101 (IL13R 2 targeted CAR-T cell therapy) and MB-108 (HSV-1 oncolytic virus), for the Treatment of Recurrent Glioblastoma and High-Grade Astrocytoma
(GlobeNewswire)
Sep-07-23 08:15AM
Mustang Bio to Participate in Upcoming September 2023 Investor Conferences
(GlobeNewswire)
Aug-16-23 08:00AM
Mustang Bio Announces First Data from Ongoing Multicenter Phase 1/2 Clinical Trial Evaluating MB-106 CAR-T Cell Therapy
(GlobeNewswire)
Aug-14-23 04:05PM
Mustang Bio Reports Second Quarter 2023 Financial Results and Recent Corporate Highlights
(GlobeNewswire) -11.04% -5.71%
04:01PM
Fortress Biotech Reports Second Quarter 2023 Financial Results and Recent Corporate Highlights
(GlobeNewswire)
Aug-03-23 08:00AM
Mustang Bio to Participate in Two August 2023 Investor Conferences
(GlobeNewswire)
Jul-31-23 08:30AM
Mustang Bio Announces Amendment and Closing of Strategic Manufacturing Partnership Transaction with uBriGene (Boston) Biosciences
(GlobeNewswire) +8.56%
Jul-06-23 08:00AM
Mustang Bio Announces Participation in Upcoming Scientific Meetings
(GlobeNewswire) -5.78%
Jun-15-23 04:01PM
Mustang Bio Announces Final Results from Follicular Lymphoma Cohort of Single-Institution Phase 1/2 Clinical Trial of MB-106, CD20-Targeted Autologous CAR T Therapy
(GlobeNewswire) +10.76% +9.44%
Jun-13-23 01:49PM
Mustang (MBIO) Up 9% on Rare Blood Cancer Study's Upbeat Data
(Zacks) -6.29%
Jun-12-23 09:55AM
Wall Street Analysts Think Mustang Bio, Inc. (MBIO) Could Surge 331.15%: Read This Before Placing a Bet
(Zacks) +9.16%
08:00AM
Mustang Bio Announces Updated Results from Waldenstrom Macroglobulinemia Cohort of Ongoing Phase 1/2 Clinical Trial of MB-106, CD20-Targeted Autologous CAR T Therapy
(GlobeNewswire)
May-26-23 09:55AM
Wall Street Analysts Believe Mustang Bio, Inc. (MBIO) Could Rally 711.55%: Here's is How to Trade
(Zacks)
May-18-23 08:03AM
Mustang Bio Announces Strategic Manufacturing Partnership and Portfolio Updates
(GlobeNewswire)
May-15-23 04:01PM
Fortress Biotech Reports First Quarter 2023 Financial Results and Recent Corporate Highlights
(GlobeNewswire) -6.65%
May-12-23 04:05PM
Mustang Bio Reports First Quarter 2023 Financial Results and Recent Corporate Highlights
(GlobeNewswire)
May-11-23 04:03PM
Mustang Bio Announces Upcoming Presentations of Clinical Data from Phase 1/2 Trial of MB-106, a CD20-Targeted Autologous CAR T Cell Therapy
(GlobeNewswire)
Apr-03-23 12:15PM
Mustang Bio Announces Reverse Stock Split
(GlobeNewswire) -11.32%
Mar-30-23 04:10PM
Fortress Biotech Reports Record 2022 Financial Results and Recent Corporate Highlights
(GlobeNewswire) +6.30%
Mar-29-23 04:15PM
Mustang Bio Reports Full-Year 2022 Financial Results and Recent Corporate Highlights
(GlobeNewswire)
Mar-28-23 08:30AM
Mustang Bio to Participate in Cantors The Future of Oncology Virtual Symposium
(GlobeNewswire)
Jan-17-23 08:15AM
Mustang Bio to Participate in the B. Riley Securities 3rd Annual Oncology Conference
(GlobeNewswire) +9.19%
Dec-19-22 08:30AM
Mustang Bio Provides CAR T Cell Therapy Portfolio Updates and 2023 Anticipated Milestones
(GlobeNewswire) -10.09%
Nov-14-22 04:05PM
Mustang Bio Reports Third Quarter 2022 Financial Results and Recent Corporate Highlights
(GlobeNewswire)
Oct-27-22 08:00AM
Mustang Bio Announces Phase 1/2 Clinical Trial Data of MB-106, a First-in-Class CD20-targeted, Autologous CAR T Cell Therapy, to be Presented at 11th International Workshop for Waldenstrom's Macroglobulinemia
(GlobeNewswire) +5.17%
Oct-06-22 08:30AM
Mustang Bio Announces First Patient Treated in Its Multicenter Phase 1/2 Clinical Trial of MB-106, a First-in-Class CD20-targeted, Autologous CAR T Cell Therapy to Treat B-cell Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia
(GlobeNewswire)
Sep-08-22 08:00AM
Mustang Bio to Participate in Upcoming September 2022 Investor Conferences
(GlobeNewswire)
Sep-02-22 09:55AM
Here's Why Mustang Bio, Inc. (MBIO) Looks Ripe for Bottom Fishing
(Zacks)
Aug-11-22 04:05PM
Mustang Bio Reports Second Quarter 2022 Financial Results and Recent Corporate Highlights
(GlobeNewswire)
Jul-27-22 08:00AM
Mustang Bio Announces First Patient Successfully Treated by Ex Vivo Lentiviral Gene Therapy to Treat RAG1 Severe Combined Immunodeficiency
(GlobeNewswire)
Jul-17-22 08:21AM
Mustang Bio, Inc. (NASDAQ:MBIO) insider upped their holding by 9.9% earlier this year
(Simply Wall St.)
Jun-22-22 08:00AM
Mustang Bio Announces Orphan Drug Designation Granted to MB-106, a CD20-targeted, Autologous CAR T Cell Therapy for the Treatment of Waldenstrom Macroglobulinemia
(GlobeNewswire) +12.57%
Jun-13-22 08:00AM
Mustang Bio Announces Updated Interim Results from Follicular Lymphoma Cohort of Ongoing Phase 1/2 Clinical Trial of MB-106, CD20-Targeted CAR T Therapy
(GlobeNewswire)
May-19-22 03:23PM
Mustang Bio Posts Encouraging Interim Data From Gene Therapy Trial In Immunodeficiency
(Benzinga)
08:45AM
Mustang Bio Announces Updated Interim Data on X-Linked Severe Combined Immunodeficiency Treatment with Lentiviral Vector Gene Therapy Support Upcoming Multicenter Pivotal Phase 2 Trial for MB-107
(GlobeNewswire)
May-12-22 04:05PM
Mustang Bio Reports First Quarter 2022 Financial Results and Recent Corporate Highlights
(GlobeNewswire) +5.56%
10:38AM
Mustang Bio Announces Results from Follicular Lymphoma Cohort of Ongoing Phase 1/2 Clinical Trial of MB-106, CD20-Targeted CAR T Therapy, Selected for Oral Presentation at European Hematology Association 2022 Hybrid Congress
(GlobeNewswire)
May-03-22 08:00AM
Mustang Bio Announces Data on Treatment with Lentiviral Viral Vector Gene Therapy for X-Linked Severe Combined Immunodeficiency Selected for Oral Presentation at American Society of Gene & Cell Therapy 25th Annual Meeting
(GlobeNewswire) -5.35%
Apr-25-22 08:00AM
Mustang Bio Announces Updated Interim Phase 1/2 Data for MB-106, CD20-Targeted CAR T Therapy, in Patients with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia
(GlobeNewswire)
Apr-21-22 08:30AM
Mustang Bio Announces Upcoming MB-106 CD20-Targeted CAR T Data Presentations
(GlobeNewswire) -5.16%
Apr-13-22 10:00AM
Mustang Bio Announces a Phase 1 Clinical Trial Combining MB-101 (IL13R2targeted CAR T cell therapy) and MB-108 (C134 oncolytic virus) for the Treatment of Glioblastoma
(GlobeNewswire)
Apr-04-22 08:00AM
Mustang Bio to Present at the Virtual Fortress Biotech R&D Summit Hosted by B. Riley Securities
(GlobeNewswire) +8.65%
Apr-01-22 08:30AM
Fortress Biotech Announces Virtual Two-Day R&D Summit Hosted by B. Riley Securities on Tuesday, April 5 and Wednesday, April 6, 2022
(GlobeNewswire)
Mar-23-22 04:05PM
Mustang Bio Reports Full-Year 2021 Financial Results and Recent Corporate Highlights
(GlobeNewswire) -9.71% +22.58%
Mar-10-22 08:30AM
Mustang Bio to Participate in Three March 2022 Investor Conferences
(GlobeNewswire) -6.41%
Mar-09-22 08:00AM
Mustang Bio Announces City of Hope, University of Alabama at Birmingham and Nationwide Childrens Hospital Abstract Accepted for Late-Breaker Poster Presentation at the American Association for Cancer Research (AACR) Annual Meeting 2022
(GlobeNewswire) +14.18%
Mar-08-22 09:00AM
Mustang Bio Completes a $75 Million Debt Financing with Runway Growth Capital
(GlobeNewswire)
Feb-15-22 07:30AM
Mustang Bio Announces City of Hope MB-105 Prostate Stem Cell Antigen CAR T Data Selected for Presentation at the 2022 American Society of Clinical Oncology Genitourinary Cancers Symposium
(GlobeNewswire) +6.93%
Feb-08-22 08:30AM
Mustang Bio Selected as a Bronze Winner in Eighteenth Annual Team Massachusetts Economic Impact Awards
(GlobeNewswire)
Feb-07-22 09:11AM
One Mustang Bio, Inc. (NASDAQ:MBIO) insider upped their stake by 25% in the previous year
(Simply Wall St.)
Jan-25-22 07:10AM
FDA Holds Mustang Bio's Gene Therapy IND For Compromised Immune System Disorder
(Benzinga) -6.15%
Jan-24-22 05:00PM
Mustang Bio Provides an Update on its IND Application for MB-207, a Lentiviral Gene Therapy for Treatment of X-linked Severe Combined Immunodeficiency (XSCID) in Previously Transplanted Patients
(GlobeNewswire)
Jan-07-22 02:05PM
Mustang Bio Announces MB-106 CD20-Targeted CAR T Data Selected for Presentation at the 2022 Tandem Meetings I Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR
(GlobeNewswire)
Jan-05-22 08:30AM
Mustang Bio to Participate in Three January 2022 Virtual Investor Conferences
(GlobeNewswire) -5.26%
Dec-16-21 08:30AM
Mustang Bio Added to the NASDAQ Biotechnology Index
(GlobeNewswire)
Dec-13-21 09:00AM
Mustang Bio Announces Updated Interim Phase 1/2 Data for MB-106 in Patients with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia
(GlobeNewswire) -11.59%
Dec-09-21 08:30AM
Mustang Bio to Host Key Opinion Leader Webinar on MB-106, a Potential Treatment for B-Cell Non Hodgkin Lymphomas and Chronic Lymphocytic Leukemia
(GlobeNewswire)
Dec-06-21 07:30AM
Here's Why We're Watching Mustang Bio's (NASDAQ:MBIO) Cash Burn Situation
(Simply Wall St.)
Nov-12-21 08:05AM
Mustang Bio Reports Third Quarter 2021 Financial Results and Recent Corporate Highlights
(GlobeNewswire)
Mustang Bio, Inc. is a clinical-stage biopharmaceutical company, which engages in the translation of medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors, and rare genetic diseases. Its pipeline includes CAR T therapies for hematologic malignancies, CAR T therapies for solid tumors, and gene therapies for rare genetic disorders. The company was founded on March 13, 2015 and is headquartered in Waltham, MA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Herskowitz NeilDirectorDec 30 '25Sale0.96247238145Dec 30 04:17 PM
Chill Adam J.DirectorDec 30 '25Sale0.9544375Dec 30 04:16 PM
Jin DavidDirectorDec 30 '25Buy0.96247238286Dec 30 04:15 PM
open in screener | open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR
Open in Screener

FBIO

Fortress Biotech Inc

Last Close
Dec 30  •  04:00PM ET
3.58
Dollar change
0.00
Percentage change
0.00 %
Healthcare • Biotechnology • USA • NASD
FBIO Fortress Biotech Inc daily Stock Chart
Peers: BMRN FOLD PTGX XENE MGTX TGTX QURE ANAB CRSP EDIT
 | Held by: VTI VXF IWC
Index- P/E- EPS (ttm)-0.27 Insider Own20.13% Shs Outstand31.01M Perf Week-1.10%
Market Cap111.12M Forward P/E- EPS next Y-0.60 Insider Trans0.00% Shs Float24.79M Perf Month26.95%
Enterprise Value102.51M PEG- EPS next Q-0.20 Inst Own15.19% Short Float14.62% Perf Quarter-3.11%
Income-5.34M P/S1.78 EPS this Y97.03% Inst Trans-1.42% Short Ratio5.74 Perf Half Y96.70%
Sales62.30M P/B1.99 EPS next Y-650.00% ROA2.58% Short Interest3.62M Perf YTD76.79%
Book/sh1.80 P/C1.29 EPS next 5Y- ROE10.35% 52W High4.20 -14.76% Perf Year73.79%
Cash/sh2.78 P/FCF- EPS past 3/5Y39.06% 24.49% ROIC-4.59% 52W Low1.33 170.19% Perf 3Y-55.56%
Dividend Est.- EV/EBITDA- Sales past 3/5Y-5.71% 9.50% Gross Margin60.21% Volatility4.94% 6.54% Perf 5Y-93.12%
Dividend TTM- EV/Sales1.65 EPS Y/Y TTM94.05% Oper. Margin-149.18% ATR (14)0.20 Perf 10Y-90.57%
Dividend Ex-Date- Quick Ratio1.97 Sales Y/Y TTM-0.32% Profit Margin-8.57% RSI (14)65.60 Recom1.00
Dividend Gr. 3/5Y- - Current Ratio2.19 EPS Q/Q114.54% SMA2011.37% Beta1.45 Target Price10.75
Payout- Debt/Eq1.22 Sales Q/Q20.52% SMA5025.85% Rel Volume0.34 Prev Close3.58
Employees101 LT Debt/Eq1.08 EarningsNov 14 BMO SMA20053.46% Avg Volume631.80K Price3.58
IPONov 17, 2011 Option/ShortYes / Yes EPS/Sales Surpr.126.19% -16.12% Trades Volume234,394 Change0.00%
Date Action Analyst Rating Change Price Target Change
Mar-15-24Resumed ROTH MKM Buy $10
Aug-04-22Initiated Ladenburg Thalmann Buy $6
Oct-02-20Initiated The Benchmark Company Buy $9
Dec-18-19Initiated B. Riley FBR Buy $9
Feb-28-18Initiated B. Riley FBR, Inc. Buy $10
Jul-11-17Initiated Rodman & Renshaw Buy $11
Mar-22-17Initiated JMP Securities Mkt Outperform
Oct-03-16Initiated ROTH Capital Buy $9
Dec-15-25 08:00AM
Fortress Biotech and Cyprium Therapeutics Announce FDA Acceptance of CUTX-101 NDA Resubmission
(GlobeNewswire) +13.31%
Dec-10-25 08:30AM
Journey Medical Corporation Announces Publication of Clinical Trial Results Assessing the Impact of Emrosi (DFD-29) on Microbial Flora of Healthy Adults in the Journal of Drugs in Dermatology
(GlobeNewswire)
Nov-14-25 09:40AM
Fortress Biotech (FBIO) Surpasses Q3 Earnings Estimates
(Zacks) +5.22%
08:40AM
Fortress Biotech: Q3 Earnings Snapshot
(Associated Press Finance)
08:30AM
Fortress Biotech Reports Third Quarter 2025 Financial Results and Recent Corporate Highlights
(GlobeNewswire)
05:25PM Loading…
Nov-12-25 05:25PM
Armata Pharmaceuticals, Inc. (ARMP) Reports Q3 Loss, Misses Revenue Estimates
(Zacks)
04:01PM
Journey Medical Corporation Reports Third Quarter 2025 Financial Results and Recent Corporate Highlights
(GlobeNewswire)
Nov-10-25 08:15AM
Kamada (KMDA) Misses Q3 Earnings Estimates
(Zacks)
Nov-06-25 05:45PM
Prothena (PRTA) Reports Q3 Loss, Lags Revenue Estimates
(Zacks)
Nov-05-25 08:30AM
Journey Medical Corporation to Announce Third Quarter 2025 Financial Results on November 12, 2025
(GlobeNewswire)
Nov-04-25 05:15PM
Ultragenyx (RARE) Reports Q3 Loss, Misses Revenue Estimates
(Zacks)
Oct-30-25 08:15AM
Apellis Pharmaceuticals, Inc. (APLS) Q3 Earnings and Revenues Top Estimates
(Zacks)
Oct-24-25 08:30AM
Journey Medical Corporation Reports Combined Emrosi (DFD-29) Phase 3 Clinical Trial Efficacy Data Analysis Presented at the 2025 Fall Clinical Dermatology Conference
(GlobeNewswire)
Oct-21-25 08:30AM
Fortress Biotech and Subsidiary Urica Therapeutics Announce First Patients Dosed in Crystalys Therapeutics' Global Phase 3 Trials of Dotinurad for the Treatment of Gout
(GlobeNewswire)
Oct-08-25 08:30AM
Journey Medical Corporation to Participate in October 2025 Investor Conferences
(GlobeNewswire)
08:05AM Loading…
Oct-01-25 08:05AM
Fortress Biotech and Subsidiary Urica Therapeutics Announce Crystalys Therapeutics' $205 Million Series A Financing
(GlobeNewswire) -30.72%
08:00AM
Fortress Biotech and Cyprium Therapeutics Announce an Update on the NDA for CUTX-101
(GlobeNewswire)
Sep-03-25 08:30AM
Journey Medical Corporation to Participate in September 2025 Investor Conferences
(GlobeNewswire)
Sep-02-25 08:30AM
Fortress Biotech to Present at the H.C. Wainwright 27th Annual Global Investment Conference
(GlobeNewswire) +15.50%
Aug-18-25 08:30AM
Journey Medical Corporation to Present at the Emerging Growth Conference
(GlobeNewswire) +6.13%
Aug-14-25 05:55PM
Fortress Biotech (FBIO) Reports Q2 Loss, Beats Revenue Estimates
(Zacks) +8.16%
04:49PM
Fortress Biotech: Q2 Earnings Snapshot
(Associated Press Finance)
04:05PM
Fortress Biotech Reports Second Quarter 2025 Financial Results and Recent Corporate Highlights
(GlobeNewswire)
Aug-12-25 04:01PM
Journey Medical Corporation Reports Second Quarter 2025 Financial Results and Recent Corporate Highlights
(GlobeNewswire)
Aug-08-25 08:10AM
Repare Therapeutics Inc. (RPTX) Reports Q2 Loss, Misses Revenue Estimates
(Zacks)
Aug-07-25 06:25PM
Coherus Oncology (CHRS) Reports Q2 Loss, Beats Revenue Estimates
(Zacks)
08:30AM
Journey Medical Corporation to Ring Nasdaq Stock Market Closing Bell on August 11
(GlobeNewswire)
Aug-05-25 04:01PM
Journey Medical Corporation to Announce Second Quarter 2025 Financial Results on August 12, 2025
(GlobeNewswire)
Jul-14-25 08:50AM
Why Fast-paced Mover Fortress Biotech (FBIO) Is a Great Choice for Value Investors
(Zacks)
08:30AM
Journey Medical Corporation Announces Expanded Payer Coverage for Emrosi
(GlobeNewswire)
09:19AM Loading…
Jul-10-25 09:19AM
Ultragenyx (RARE) Surges 5.1%: Is This an Indication of Further Gains?
(Zacks)
Jun-24-25 08:30AM
Journey Medical to Join Russell 2000 and Russell 3000 Indexes
(GlobeNewswire)
Jun-20-25 08:30AM
Journey Medical Corporation Announces Emrosi Data Analysis to be Presented at the Society of Dermatology Physician Associates (SDPA) 2025 Annual Summer Dermatology Conference
(GlobeNewswire)
Jun-19-25 08:50AM
Despite Fast-paced Momentum, Fortress Biotech (FBIO) Is Still a Bargain Stock
(Zacks)
Jun-09-25 08:30AM
Journey Medical Corporation Announces Emrosi Featured on "The Balancing Act" Airing on Lifetime TV
(GlobeNewswire) +6.50%
Jun-03-25 08:50AM
Fortress Biotech (FBIO) Is Attractively Priced Despite Fast-paced Momentum
(Zacks)
May-30-25 10:47AM
Fortress Biotech Announces Closing of Sale of Subsidiary Checkpoint Therapeutics
(GlobeNewswire)
May-16-25 05:50AM
New Strong Sell Stocks for May 16th
(Zacks)
May-15-25 05:30PM
Fortress Biotech (FBIO) Reports Q1 Loss, Tops Revenue Estimates
(Zacks) +7.23%
04:25PM
Fortress Biotech: Q1 Earnings Snapshot
(Associated Press Finance)
04:05PM
Fortress Biotech Reports First Quarter 2025 Financial Results and Recent Corporate Highlights
(GlobeNewswire)
08:15AM
Precision BioSciences (DTIL) Reports Q1 Loss, Lags Revenue Estimates
(Zacks)
May-14-25 05:15PM
ScPharmaceuticals, Inc. (SCPH) Reports Q1 Loss, Misses Revenue Estimates
(Zacks)
04:01PM
Journey Medical Corporation Reports First Quarter 2025 Financial Results and Recent Corporate Highlights
(GlobeNewswire)
May-13-25 05:20PM
Exelixis (EXEL) Surpasses Q1 Earnings and Revenue Estimates
(Zacks) +5.45%
04:15PM
Checkpoint Therapeutics Reports First Quarter Financial Results and Recent Corporate Updates
(GlobeNewswire)
May-08-25 08:50AM
Wave Life Sciences (WVE) Reports Q1 Loss, Lags Revenue Estimates
(Zacks)
May-07-25 04:01PM
Journey Medical Corporation to Announce First Quarter 2025 Financial Results on May 14, 2025
(GlobeNewswire)
08:00AM
Fortress Biotech to Participate in the H.C. Wainwright 1st Annual Royalty Company Virtual Conference
(GlobeNewswire)
Apr-01-25 04:01PM
Journey Medical Corporation Appoints Ramsey Alloush as Chief Operating Officer
(GlobeNewswire)
Mar-31-25 05:50PM
Fortress Biotech (FBIO) Reports Q4 Loss, Lags Revenue Estimates
(Zacks)
04:05PM
Fortress Biotech Reports 2024 Financial Results and Recent Corporate Highlights
(GlobeNewswire)
Mar-28-25 08:30AM
Checkpoint Therapeutics Reports Full-Year 2024 Financial Results and Recent Corporate Updates
(GlobeNewswire) -6.94%
Mar-26-25 07:39PM
Fortress Biotech, Inc. (FBIO) Q4 2024 Earnings Call Transcript
(SeekingAlpha)
04:01PM
Journey Medical Corporation Reports Full-Year 2024 Financial Results and Recent Corporate Highlights
(GlobeNewswire)
Mar-25-25 09:04AM
Fortress Biotech Inc (FBIO) Q4 2024: Everything You Need To Know Ahead Of Earnings
(GuruFocus.com)
Mar-24-25 08:30AM
Journey Medical Corporation Launches Emrosi (40 mg Minocycline Hydrochloride Modified-Release Capsules, 10 mg immediate release and 30 mg extended release) for the Treatment of Rosacea
(GlobeNewswire)
Mar-19-25 04:01PM
Journey Medical Corporation to Announce Year End 2024 Financial Results on March 26, 2025
(GlobeNewswire)
Mar-17-25 08:55AM
Partex and Fortress Biotech Announce Strategic Collaboration to Accelerate Asset Identification and Evaluation Using Proprietary AI Platform
(GlobeNewswire)
Mar-14-25 12:15PM
Biotech Alert: Searches spiking for these stocks today
(TipRanks)
Mar-12-25 08:30AM
Journey Medical Corporation to Participate in the 37th Annual ROTH Conference
(GlobeNewswire)
Mar-09-25 10:06PM
Sun Pharma to Acquire Checkpoint Therapeutics
(PR Newswire)
Mar-05-25 04:15PM
Mustang Bio Regains Compliance with Nasdaq Capital Market Requirement
(GlobeNewswire)
04:01PM
Journey Medical Corporation Announces Publication in the Journal of the American Medical Association - Dermatology of the Phase 3 Clinical Trial Results of Emrosi (DFD-29) to Treat Rosacea
(GlobeNewswire)
Mar-04-25 04:01PM
Journey Medical Corporation to Exhibit at the 2025 American Academy of Dermatology Annual Meeting in Orlando, Florida
(GlobeNewswire)
Feb-27-25 04:05PM
Mustang Bio Announces Sale of Fixed Assets and Exit of Facility
(GlobeNewswire)
Feb-11-25 04:10PM
Mustang Bio Regains Compliance with Nasdaq Minimum Bid Price Requirement
(GlobeNewswire)
Feb-10-25 08:00AM
Mustang Bio Announces Closing of $8 Million Public Offering
(GlobeNewswire)
Feb-06-25 07:00AM
Mustang Bio Announces Pricing of $8 Million Public Offering
(GlobeNewswire)
Jan-28-25 08:41AM
Fortress Biotech announces first patient dosed in Phase 2 trial of Triplex
(TipRanks)
07:21AM
Fortress doses first subject in Phase II CMV vaccine trial
(Clinical Trials Arena)
Jan-27-25 08:30AM
Fortress Biotech Announces First Patient Dosed in Phase 2 Clinical Trial of Triplex Vaccination in Stem Cell Donors to Reduce CMV Events in Recipients of HSCT
(GlobeNewswire)
Jan-23-25 08:30AM
Journey Medical Corporation to Host Conference Call to Discuss U.S. Commercial Launch Plan for Emrosi (Minocycline Hydrochloride Extended Release Capsules, 40 mg) for the Treatment of Rosacea
(GlobeNewswire)
Jan-14-25 08:00AM
Mustang Bio Announces Reverse Stock Split
(GlobeNewswire)
Jan-07-25 06:59AM
FDA accepts Sentynls Menkes disease therapy NDA for priority review
(Pharmaceutical Technology)
Jan-06-25 08:00AM
Sentynl Therapeutics Announces U.S. FDA Acceptance and Priority Review of New Drug Application for CUTX-101 (Copper Histidinate) Product Candidate for Treatment of Menkes Disease
(PR Newswire)
08:00AM
Fortress Biotech and Cyprium Therapeutics Announce U.S. FDA Acceptance and Priority Review of NDA for CUTX-101 for Treatment of Menkes Disease
(GlobeNewswire)
Dec-13-24 06:15PM
Checkpoint Therapeutics Announces FDA Approval of UNLOXCYT (cosibelimab-ipdl)
(GlobeNewswire)
Nov-14-24 05:04PM
Fortress Biotech: Q3 Earnings Snapshot
(Associated Press Finance) -8.92%
04:10PM
Fortress Biotech Reports Third Quarter 2024 Financial Results and Recent Corporate Highlights
(GlobeNewswire)
04:05PM
Avenue Therapeutics Reports Third Quarter 2024 Financial Results and Recent Corporate Highlights
(GlobeNewswire)
Nov-12-24 04:30PM
Checkpoint Therapeutics Reports Third Quarter 2024 Financial Results and Recent Corporate Updates
(GlobeNewswire)
04:01PM
Journey Medical Corporation Reports Third Quarter 2024 Financial Results and Recent Corporate Highlights
(GlobeNewswire)
08:30AM
Mustang Bio Receives Positive Listing Determination from Nasdaq
(GlobeNewswire)
Nov-07-24 08:30AM
Mustang Bio Granted Orphan Drug Designation by U.S. FDA for MB-108 (HSV-1 oncolytic virus) to Treat Malignant Glioma
(GlobeNewswire)
Nov-04-24 07:00AM
Journey Medical Corporation Announces U.S. FDA Approval of Emrosi (Minocycline Hydrochloride Extended Release Capsules, 40 mg) for the Treatment of Rosacea
(GlobeNewswire) -8.95%
Oct-25-24 01:02PM
Highbridge Capital Management's Strategic Acquisition of Fortress Biotech Shares
(GuruFocus.com) +6.94%
08:30AM
Journey Medical Corporation Announces DFD-29 Data Presented at 44th Fall Clinical Dermatology Conference
(GlobeNewswire)
Oct-24-24 02:10PM
Mustang Bio Announces Exercise of Warrants for $4 Million Gross Proceeds
(GlobeNewswire)
Oct-09-24 08:30AM
Avenue Therapeutics to Participate in Maxim Group's 2024 Healthcare Virtual Summit
(GlobeNewswire)
Oct-03-24 08:30AM
Journey Medical Corporation to Participate in the 3rd Annual ROTH Healthcare Opportunities Conference
(GlobeNewswire)
Sep-26-24 08:30AM
Fortress Biotech to Participate in October 2024 Investor Conferences
(GlobeNewswire)
Sep-20-24 08:30AM
Fortress Biotech Announces Pricing of $8 Million Registered Direct Offering and Concurrent Private Placements
(GlobeNewswire) -18.75%
Sep-16-24 07:30AM
Checkpoint Therapeutics Announces Cosibelimab Longer-Term Results in Advanced Cutaneous Squamous Cell Carcinoma Presented at ESMO Congress 2024
(GlobeNewswire)
Sep-09-24 08:30AM
Journey Medical Corporation to Participate in the Lake Street Capital Markets 8th Annual Best Ideas Growth (BIG) Conference
(GlobeNewswire)
Sep-04-24 08:30AM
Fortress Biotech to Present at the H.C. Wainwright 26th Annual Global Investment Conference
(GlobeNewswire) -5.08%
08:15AM
Journey Medical Corporation to Present at the H.C. Wainwright 26th Annual Global Investment Conference
(GlobeNewswire)
08:00AM
Checkpoint Therapeutics to Present at H.C. Wainwright 26th Annual Global Investment Conference
(GlobeNewswire)
Sep-03-24 08:30AM
Avenue Therapeutics to Participate in Upcoming Investor Conferences
(GlobeNewswire)
Sep-02-24 08:50AM
Fortress Biotech (FBIO) Shows Fast-paced Momentum But Is Still a Bargain Stock
(Zacks)
Fortress Biotech, Inc. engages in the manufacture and commercialization of novel pharmaceutical products and product candidates. It operates through the Dermatology Product Sales and Pharmaceutical and Biotechnology Product Development segments. Its products include Ximino, Targadox, Exelderm, Ceracade, and Luxamend. The company was founded in 2006 and is headquartered in Bay Harbor Islands, FL.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Fortress Biotech, Inc.10% OwnerMay 29 '25Sale1.29100,000129,0006,122,249Jun 03 06:34 PM
open in screener | open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR
Affiliate • Advertise • Careers • Contact • Blog • Help • Privacy • Follow us on X • Do Not Sell My Personal Information
Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
Copyright © 2007-2025 Finviz.com. All Rights Reserved.